Compare ATI & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATI | DGX |
|---|---|---|
| Founded | 1960 | 1967 |
| Country | United States | United States |
| Employees | 7600 | N/A |
| Industry | Steel/Iron Ore | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6B | 23.1B |
| IPO Year | 1996 | 1996 |
| Metric | ATI | DGX |
|---|---|---|
| Price | $161.38 | $191.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 12 |
| Target Price | $138.44 | ★ $208.92 |
| AVG Volume (30 Days) | ★ 1.9M | 646.7K |
| Earning Date | 04-30-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.74% |
| EPS Growth | 11.76 | ★ 13.78 |
| EPS | 2.85 | ★ 8.75 |
| Revenue | $4,043,500,000.00 | ★ $11,035,000,000.00 |
| Revenue This Year | $9.56 | $7.53 |
| Revenue Next Year | $8.67 | $3.77 |
| P/E Ratio | $55.90 | ★ $22.63 |
| Revenue Growth | N/A | ★ 11.78 |
| 52 Week Low | $43.96 | $160.02 |
| 52 Week High | $168.14 | $213.50 |
| Indicator | ATI | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 62.03 | 37.45 |
| Support Level | $137.66 | $176.61 |
| Resistance Level | $165.34 | $191.91 |
| Average True Range (ATR) | 5.46 | 4.46 |
| MACD | 1.54 | -0.27 |
| Stochastic Oscillator | 94.64 | 10.95 |
ATI Inc supplies specialty metals to various end markets, including aerospace and defense, oil and gas, automotive, and electrical energy, among many others. The company's operating segment includes High-Performance Materials and Components and Advanced Alloys and Solutions. The majority of revenue is from the High-Performance Materials segment. The High-Performance Materials segment is focused on a wide range of high-performance specialty materials, parts, and components for several the majority of end markets, including the aerospace & defense, medical, and energy markets. Geographically, it operates in the United States, China, the United Kingdom, Germany, France, Canada, and Others, the majority is from the United States.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.